Ranibizumab versus aflibercept for the treatment of vascularized pigment epithelium detachment due to age-related macular degeneration

• Published in: International ophthalmology 2019-02, Vol.39 (2), p.431-440
• Main Authors: Rouvas, Alexandros, Chatziralli, Irini, Androu, Angeliki, Mpougatsou, Panagiota, Alonistiotis, Dimitrios, Douvali, Maria, Kabanarou, Stamatina A., Theodossiadis, Panagiotis
• Format: Article
• Language: English
• Subjects: Acuity; Age; Age related diseases; Edema; Epithelium; Eye (anatomy); Immunotherapy; Macular degeneration; Medicine; Medicine & Public Health; Monoclonal antibodies; Ophthalmology; Optical Coherence Tomography; Original Paper; Patients; Statistical analysis; Vascular endothelial growth factor; Visual acuity
• ISSN: 0165-5701; 1573-2630
• DOI: 10.1007/s10792-018-0833-2

Purpose To compare the efficacy and safety of two intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents, ranibizumab and aflibercept, for the treatment of vascularized pigment epithelium detachment (vPED) due to age-related macular degeneration (AMD) in a follow-up time of 12 months. Methods Participants in this study were 71 patients (71 eyes) with vPED due to AMD, who were treated with intravitreal 0.5 mg ranibizumab ( n  = 38) or 2.0 mg aflibercept ( n  = 33) and had at least 12-month follow-up. All patients underwent best-corrected visual acuity (BCVA) measurement and optical coherence tomography at baseline and at every visit. The PED height, the presence of subretinal fluid (SRF), intraretinal fluid and diffuse macular edema (DME) were recorded at each visit. Results There was a statistically significant difference in BCVA between the two groups at month 12 in favor of aflibercept. However, both agents were found to improve or stabilize BCVA in the majority of patients at the end of the follow-up. The change in PED height did not differ significantly between the two groups at the end of the follow-up with similar number of injections. At month 12, there was a significant improvement in SRF presence in both groups compared to baseline. Conclusions Although aflibercept was found to be superior to ranibizumab regarding BCVA improvement, both agents showed anatomical effectiveness with significant reduction in PED height and SRF absorption in patients with vPED due to AMD.